Stories

Public health can fail quietly when it counts intentions more carefully than consequences. Campaigns, restrictions and official messages may be designed to protect people, yet still produce confusion, mistrust or worse choices in the real world. Nicotine policy is a clear example: caution becomes harmful when it hides the difference between smoking and lower-risk alternatives. A stronger public health culture would measure what its advice actually does, not only what it was meant to do.

A 264% price hike is not a small adjustment for people who have moved from smoking to vaping. Price can decide whether a lower-risk product remains usable, especially for adults managing dependence, budgets and the temptation to return to cigarettes. Vape duty should not make the safer legal option feel like a luxury or push consumers towards cheaper illicit products. Tax policy needs to support the shift away from combustion, not penalise it.

For many people, the route away from smoking is not one clean break but a transition. The latest GSTHR Briefing Paper looks at emerging shifts from cigarettes to safer nicotine products across countries, showing how people reduce risk by changing the way they use nicotine. These country-level patterns matter because they reveal what happens when alternatives are available, acceptable and understood. Tobacco policy should learn from those real-world transitions instead of treating continued nicotine use as a failure.

Toxicity is where the nicotine debate needs less rhetoric and more comparison. A major review finding nicotine pouches considerably less toxic than cigarettes reinforces the basic harm reduction point: the way nicotine is delivered changes the risk profile. Smoke-free does not mean risk-free, but it does mean the absence of combustion and far lower exposure to many harmful toxicants. Policy should reflect that difference instead of treating pouches and cigarettes as interchangeable threats.

Insurance pricing can reveal how poorly nicotine risk is understood. Treating every nicotine user like a smoker ignores the difference between combustible tobacco and smoke-free alternatives such as pouches, snus or vaping. That matters because premiums can punish people who have reduced their risk by leaving cigarettes behind. A fairer approach would price risk according to evidence, exposure and product type — not according to nicotine use alone.

Vape prohibitions promise control, but their real legacy is often a messier market. Legal products disappear from view, illicit sellers gain room to operate, and adult smokers lose one of the most accessible routes away from cigarettes. The policy may look firm, yet the behaviour it tries to stop simply moves elsewhere. Harm reduction starts from that reality: people need safer options that are legal, regulated and easier to choose than the dangerous ones.

Haypp’s move into the US nicotine pouch market reflects more than business expansion. It signals growing consumer demand for smoke-free products that are convenient, discreet and separate from combustion. That shift matters because markets can either be shaped through responsible standards or left to develop without enough oversight. A strong harm reduction framework should make room for adult access, product accountability and clear information about where pouches sit on the risk spectrum.

Spain’s new anti-smoking law shows how easily tobacco control can expand from protecting bystanders to restricting every nicotine product in the same breath. Smoke-free spaces, youth protection and advertising rules all deserve serious attention, but policy loses precision when cigarettes, vapes and heated tobacco are treated as one problem. The goal should be less smoking and less exposure to harmful emissions, not a framework that blurs the difference between combustion and lower-risk alternatives. Strong regulation works best when it understands what it is regulating.

Nicotine pouches are gaining ground because they solve practical problems that policy often overlooks. They are smoke-free, discreet, easy to use and do not require combustion, making them a workable alternative for adults who want nicotine without cigarettes. Their success should not be treated as a mystery or a threat by default. It should be understood as a signal that consumers respond to products that fit real life while reducing exposure to the harms of smoking.

A faster FDA pathway for vapes and nicotine pouches would matter most for the legal market. Years of slow authorisations have left adult smokers with limited approved options while illicit and unapproved products fill the gap. Speed should not mean weak standards; it should mean timely, evidence-based decisions that distinguish responsible smoke-free products from those that fail basic tests. Harm reduction needs regulation that can move quickly enough to keep safer alternatives inside accountable channels.